A Phase 2 interventional study of Ruxolitinib cream and Vehicle cream in Vitiligo, sponsored by Incyte Corporation. Completed at 26 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-17.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.
Among the 14 studies testing ruxolitinib in Vitiligo, this one is the 6th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 2, and was the 2nd registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in Argentina, Austria, Belgium and 11 more countries
Ages 6–11
Incyte Corporation · Sites in United States, Canada
Ages 2–11
Hospital Authority, Hong Kong · Sites in Hong Kong
Ages 18–85
Kafrelsheikh University · Sites in Egypt
Ages 12+
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 2–11
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2016; this study’s year is marked. 1 started in 2017.
This study's enrollment of 157 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 90 across the 14 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 14 have an industry lead sponsor. The 6 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
12 studies in Vitiligo by Incyte Corporation: 2 open now, 4 under way, 4 of them phase 3. Of 8 finished, 8 (100%) have results posted.
Among the 12 studies in Vitiligo by Incyte Corporation, this one is the 9th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 2, and was the 1st registered.
Incyte Corporation’s Vitiligo studies by the year they started, since 2017.
2 of the studies testing ruxolitinib in Vitiligo that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06804811Phase 3Incyte CorporationA Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | 2027-04-30 |
| NCT07909668Kafrelsheikh UniversityTopical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing ruxolitinib in Vitiligo, from their registry updates:
Among Incyte Corporation’s 12 in Vitiligo:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Vitiligo with depigmented areas including:
Exclusion Criteria:
Participants who have received any of the following treatments within the minimum specified timeframes.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib cream 1.5% BID for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
Drug: Ruxolitinib cream
Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
Drug: Ruxolitinib cream · Drug: Vehicle cream
Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
Drug: Ruxolitinib cream · Drug: Vehicle cream
Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (opportunity for re-randomization to a higher dose at Week 24 if \< 25% improvement in F-VASI score), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
Drug: Ruxolitinib cream · Drug: Vehicle cream
Vehicle cream BID for 24 weeks, followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% QD, or 0.5% QD for Weeks 24 to 52, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
Drug: Ruxolitinib cream · Drug: Vehicle cream
Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Also known as: INCB018424 cream
Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Percentage of Participants Treated With Ruxolitinib Cream Who Achieved a ≥ 50% Improvement From Baseline in Facial Assessment of the Vitiligo Area and Severity Index Score (F-VASI50) Compared With Participants Treated With Vehicle at Week 24
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: Baseline; Week 24
Percentage of Participants Who Achieved a Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) of Clear or Almost Clear
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.
Time frame: Week 24
Percentage of Participants Who Achieved a ≥ 50% Improvement From Baseline in Full Body Assessment of Vitiligo Area and Severity Index (T-VASI) at Week 52
T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each body site and summing all values (possible range: 0-100; lower scores indicate increased improvement).
Time frame: Baseline; Week 52
Dose Response on Percentage Change From Baseline in F-VASI
Time frame: up to 156 weeks
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Grade 3 or Higher TEAE up to Week 24
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.
Time frame: up to 24 weeks
Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE up to Week 52
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.
Time frame: up to 52 weeks
Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE From Week 24 to Week 52
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.
Time frame: Week 24 to Week 52
Number of Participants Who Applied Ruxolitinib 1.5% Cream BID Throughout Study Participation With Any TEAE and Any Grade 3 or Higher TEAE
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.
Time frame: up to Week 156
Number of Participants With Any TEAE and Any Grade 3 or Higher TEAE From Week 52 to Week 156
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.
Time frame: Week 52 to Week 156
Mean Change From Baseline in F-VASI Score at Week 24
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Week 24
Mean Change From Baseline in F-VASI Score at Weeks 52, 104, and 156
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 52, 104, and 156
Percentage Change From Baseline in F-VASI Score at Week 24
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.
Time frame: Baseline; Week 24
Percentage Change From Baseline in F-VASI Score at Weeks 52, 104, and 156
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.
Time frame: Baseline; Weeks 52, 104, and 156
Percentage of Participants Who Achieved an F-VASI50 at Weeks 52, 104, and 156
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: Baseline; Weeks 52, 104, and 156
Percentage Change From Baseline in F-BSA Repigmentation at Week 24
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.
Time frame: Baseline; Week 24
Percentage Change From Baseline in F-BSA Repigmentation at Weeks 52, 104, and 156
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.
Time frame: Baseline; Weeks 52, 104, and 156
Percentage Change From Baseline in T-BSA Repigmentation at Week 24
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.
Time frame: Baseline; Week 24
Percentage Change From Baseline in T-BSA Repigmentation at Weeks 52, 104, and 156
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.
Time frame: Baseline; Weeks 52, 104, and 156
Mean Change From Baseline in T-VASI Score at Week 24
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from Baseline (BL) was calculated as the post-BL value minus the BL value.
Time frame: Baseline; Week 24
Mean Change From Baseline in T-VASI Score at Weeks 52, 104, and 156
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from BL was calculated as the post-BL value minus the BL value.
Time frame: Baseline; Weeks 52, 104, and 156
Percentage Change From Baseline in T-VASI Score at Week 24
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: Baseline; Week 24
Percentage Change From Baseline in T-VASI Score at Weeks 52, 104, and 156
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: Baseline; Weeks 52, 104, and 156
Mean Change From Baseline in Vitiligo European Task Force (VETF) Scale Scores at Week 24: Total Spreading
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
Time frame: Baseline; Week 24
Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Spreading
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
Time frame: Baseline; Weeks 52 and 104
Mean Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
Time frame: Baseline; Week 24
Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Percentage Area
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
Time frame: Baseline; Weeks 52 and 104
Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
Time frame: Baseline; Week 24
Percentage Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Percentage Area
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
Time frame: Baseline; Weeks 52 and 104
Mean Change From Baseline in VETF Scale Scores at Week 24: Total Staging
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
Time frame: Baseline; Week 24
Mean Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Staging
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
Time frame: Baseline; Weeks 52 and 104
Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Staging
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
Time frame: Baseline; Week 24
Percentage Change From Baseline in VETF Scale Scores at Weeks 52 and 104: Total Staging
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
Time frame: Baseline; Weeks 52 and 104
Percentage of Participants in Each Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) Category at Week 24
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.
Time frame: Week 24
Percentage of Participants in Each Facial Assessment of the PhGVA (F-PhGVA) Category at Weeks 52, 104 and 156
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.
Time frame: Weeks 52, 104, and 156
Percentage of Participants in Each Total Body Assessment of the PhGVA (T-PhGVA) Category at Week 24
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.
Time frame: Week 24
Percentage of Participants in Each Total Body Assessment of the PhGVA (T-PhGVA) Category at Weeks 52, 104 and 156
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.
Time frame: Weeks 52, 104, and 156
Percentage of Participants in Each Facial Assessment of the Patient's Global Vitiligo Assessment (F-PaGVA) Category at Week 24
The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.
Time frame: Week 24
Percentage of Participants in Each Facial Assessment of the PaGVA (F-PaGVA) Category at Weeks 52, 104, and 156
The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.
Time frame: Weeks 52, 104, and 156
Percentage of Participants in Each Total Body Assessment of the PaGVA (T-PaGVA) Category at Week 24
The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.
Time frame: Week 24
Percentage of Participants in Each Total Body Assessment of the PaGVA (T-PaGVA) Category at Weeks 52, 104, and 156
The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.
Time frame: Weeks 52, 104, and 156
Percentage of Participants in Each Patient Global Impression of Change for Vitiligo (PaGIC-V) Category at Week 24
The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.
Time frame: Baseline; Week 24
Percentage of Participants in Each PaGIC-V Category at Weeks 52, 104, and 156
The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.
Time frame: Baseline; Weeks 52, 104, and 156
Percentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Week 24
The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.
Time frame: Baseline; Week 24
Percentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Weeks 52, 104, and 156
The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.
Time frame: Baseline; Weeks 52, 104, and 156
Time to Achieve an F-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the F-VASI50 Score
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: up to 52 weeks
Time to Achieve a T-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the T-VASI50 Score
A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI. T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each body site and summing all values (possible range: 0-100; lower scores indicate increased improvement).
Time frame: up to 52 weeks
Time to Achieve an F-PhGVA of Clear or Almost Clear
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening. Time to achieve an F-PhGVA response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the F-PhGVA score.
Time frame: up to 52 weeks
Time to Achieve an T-PhGVA of Clear or Almost Clear
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening. Time to achieve a T-PhGVA response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the T-PhGVA score.
Time frame: up to 52 weeks
Time to Achieve a PaGIC-V of Very Much Improved or Much Improved
The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse. Time to achieve a PaGIC-V response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the PaGIC-V score.
Time frame: up to 52 weeks
A total of 157 participants with vitiligo were treated at 26 study centers in the United States.
| Milestone | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID | Cross-over |
|---|---|---|---|---|---|---|
| Started | 32 | 31 | 31 | 30 | 33 | 0 |
| Completed | 27 | 26 | 30 | 26 | 30 | 0 |
| Not completed | 5 | 5 | 1 | 4 | 3 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 0 | 2 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 | 0 | 0 |
| Milestone | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID | Cross-over |
|---|---|---|---|---|---|---|
| Started | 0 | 11 | 45 | 44 | 47 | 0 |
| Completed | 0 | 10 | 43 | 37 | 45 | 0 |
| Not completed | 0 | 1 | 2 | 7 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 4 | 1 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID | Cross-over |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 28 | 21 | 28 | 46 |
| Completed | 0 | 0 | 11 | 8 | 12 | 23 |
| Not completed | 0 | 0 | 17 | 13 | 16 | 23 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 2 | 1 | 6 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 9 | 10 | 13 | 15 |
| Withdrew: Other reason not specified | 0 | 0 | 4 | 1 | 1 | 0 |
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Percentage of Participants Treated With Ruxolitinib Cream Who Achieved a ≥ 50% Improvement From Baseline in Facial Assessment of the Vitiligo Area and Severity Index Score (F-VASI50) Compared With Participants Treated With Vehicle at Week 24 | 3.1 | 32.3 | 25.8 | 50.0 | 45.5 |
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.
| percentage of participants | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved a Facial Assessment of the Physician's Global Vitiligo Assessment (F-PhGVA) of Clear or Almost Clear | 0 | 3.2 | 9.7 | 13.3 | 9.1 |
T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each body site and summing all values (possible range: 0-100; lower scores indicate increased improvement).
| percentage of participants | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved a ≥ 50% Improvement From Baseline in Full Body Assessment of Vitiligo Area and Severity Index (T-VASI) at Week 52 | 50 | 21.4 | 16.7 | 15.4 | 25.8 | 30.0 | 36.4 |
No measurements were reported for this outcome.
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.
| Participants | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Any TEAE | 20 | 20 | 22 | 22 | 20 |
| Any Grade 3 or higher TEAE | 0 | 0 | 0 | 0 | 1 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.
| Participants | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Any TEAE | — | — | — | — | 26 | 23 | 23 |
| Any Grade 3 or higher TEAE | — | — | — | — | 2 | 1 | 1 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.
| Participants | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Any TEAE | 9 | 6 | 5 | 9 | — | — | — |
| Any Grade 3 or higher TEAE | 0 | 0 | 0 | 0 | — | — | — |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.
| Participants | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Any TEAE | — | — | — | — | — | — | 26 |
| Any Grade 3 or higher TEAE | — | — | — | — | — | — | 1 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was an AE reported for the first time or the worsening of a pre-existing event after first application of study drug. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.
| Participants | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% BID: 1.5% BID | Cross-over |
|---|---|---|---|---|
| Any TEAE | 15 | 16 | 13 | 25 |
| Any Grade 3 or higher TEAE | 0 | 2 | 0 | 2 |
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| scores on a scale | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Mean Change From Baseline in F-VASI Score at Week 24 | 0.05 ± 0.11 | -0.39 ± 0.11 | -0.35 ± 0.11 | -0.63 ± 0.11 | -0.46 ± 0.10 |
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| scores on a scale | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Baseline | 0.77 ± 0.387 | 1.21 ± 0.891 | 1.66 ± 0.993 | 1.14 ± 0.714 | 1.22 ± 0.705 | 1.45 ± 0.980 | 1.26 ± 0.808 |
| Change from Baseline at Week 52 | -0.59 ± 0.459 | -0.67 ± 0.811 | -1.02 ± 1.058 | -0.58 ± 0.783 | -0.58 ± 0.578 | -0.74 ± 0.797 | -0.76 ± 0.610 |
| Change from Baseline at Week 104 | -0.66 ± 0.444 | -0.97 ± 1.061 | -1.79 ± 1.077 | -0.87 ± 0.903 | -1.00 ± 0.697 | -1.17 ± 0.961 | -0.99 ± 0.817 |
| Change from Baseline at Week 156 | -0.66 ± 0.124 | -0.98 ± 1.092 | -1.40 ± 1.018 | -0.65 ± 0.557 | -0.71 ± 0.490 | -0.95 ± 0.949 | -1.23 ± 0.887 |
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.
| percent change | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Percentage Change From Baseline in F-VASI Score at Week 24 | 6.02 ± 7.23 | -30.69 ± 7.39 | -29.10 ± 6.93 | -40.00 ± 7.39 | -37.78 ± 6.89 |
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.
| percent change | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52 | -72.21 ± 26.837 | -50.60 ± 34.954 | -52.43 ± 36.412 | -40.79 ± 37.082 | -45.54 ± 35.148 | -55.63 ± 42.823 | -57.34 ± 50.115 |
| Week 104 | -77.67 ± 22.974 | -71.12 ± 31.087 | -82.87 ± 32.756 | -60.28 ± 64.708 | -74.89 ± 25.524 | -77.76 ± 24.086 | -78.78 ± 28.400 |
| Week 156 | -87.95 ± 8.207 | -66.83 ± 45.106 | -91.25 ± 14.631 | -59.16 ± 42.627 | -76.25 ± 20.126 | -76.76 ± 23.924 | -89.52 ± 14.899 |
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52 | 90.0 | 64.3 | 50.0 | 38.5 | 45.2 | 43.3 | 57.6 |
| Week 104 | 88.9 | 87.5 | 88.9 | 77.8 | 78.9 | 83.3 | 89.5 |
| Week 156 | 100.0 | 75.0 | 100.0 | 60.0 | 87.5 | 87.5 | 100.0 |
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.
| percent change | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Percentage Change From Baseline in F-BSA Repigmentation at Week 24 | 6.49 ± 32.028 | -19.82 ± 24.928 | -17.55 ± 25.453 | -19.53 ± 38.612 | -27.76 ± 30.996 |
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically and laterally from the corner of the mouth to the tragus. The area "Face" did not include the surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.
| percent change | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52 | -55.18 ± 36.091 | -37.94 ± 32.569 | -33.39 ± 40.095 | -15.64 ± 29.733 | -34.67 ± 37.769 | -38.37 ± 38.660 | -44.29 ± 35.253 |
| Week 104 | -42.86 ± 31.282 | -67.61 ± 29.683 | -76.57 ± 31.260 | -45.65 ± 59.599 | -54.49 ± 34.411 | -63.56 ± 28.543 | -59.49 ± 38.186 |
| Week 156 | -33.04 ± 6.313 | -59.17 ± 40.586 | -90.50 ± 16.240 | -16.89 ± 56.706 | -55.80 ± 33.310 | -59.58 ± 27.106 | -72.58 ± 31.024 |
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.
| percent change | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Percentage Change From Baseline in T-BSA Repigmentation at Week 24 | 3.35 ± 8.314 | -13.97 ± 25.396 | -10.83 ± 15.646 | -17.19 ± 22.490 | -13.60 ± 20.443 |
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline value minus Baseline value\]/Baseline value) X 100.
| percent change | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52 | -39.53 ± 32.599 | -8.72 ± 26.010 | -2.72 ± 23.014 | -8.73 ± 21.630 | -15.13 ± 21.296 | -27.33 ± 27.568 | -27.59 ± 26.770 |
| Week 104 | -42.42 ± 32.208 | -30.49 ± 36.289 | -30.08 ± 30.717 | -21.08 ± 30.323 | -33.19 ± 30.127 | -33.94 ± 26.573 | -32.46 ± 33.190 |
| Week 156 | -59.44 ± 51.920 | -46.58 ± 30.723 | -34.93 ± 35.391 | -37.95 ± 23.651 | -29.59 ± 32.261 | -10.55 ± 53.863 | -46.88 ± 19.304 |
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from Baseline (BL) was calculated as the post-BL value minus the BL value.
| scores on a scale | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Mean Change From Baseline in T-VASI Score at Week 24 | 0.57 ± 0.92 | -2.27 ± 0.94 | -2.18 ± 0.88 | -4.51 ± 0.94 | -3.52 ± 0.87 |
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from BL was calculated as the post-BL value minus the BL value.
| scores on a scale | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Baseline | 9.56 ± 7.090 | 13.47 ± 11.655 | 22.82 ± 19.187 | 20.75 ± 15.973 | 18.43 ± 15.363 | 20.55 ± 18.488 | 16.94 ± 14.256 |
| Change from Baseline at Week 52 | -4.59 ± 4.979 | -2.88 ± 2.934 | -3.21 ± 4.536 | -3.88 ± 5.642 | -3.97 ± 6.284 | -7.37 ± 7.403 | -6.14 ± 7.442 |
| Change from Baseline at Week 104 | -6.02 ± 5.476 | -5.32 ± 5.615 | -9.71 ± 9.398 | -6.62 ± 7.054 | -7.19 ± 9.079 | -10.77 ± 9.658 | -7.74 ± 5.927 |
| Change from Baseline at Week 156 | -2.33 ± 0.269 | -10.23 ± 13.533 | -11.31 ± 12.185 | -7.82 ± 4.209 | -4.72 ± 3.622 | -7.02 ± 9.577 | -8.77 ± 4.996 |
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
| percent change | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Percentage Change From Baseline in T-VASI Score at Week 24 | 2.65 ± 4.89 | -20.88 ± 5.00 | -15.82 ± 4.69 | -27.16 ± 4.99 | -22.91 ± 4.65 |
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
| percent change | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52 | -50.71 ± 33.310 | -25.12 ± 31.556 | -19.75 ± 26.484 | -20.00 ± 29.264 | -24.67 ± 29.649 | -41.90 ± 35.865 | -41.67 ± 26.451 |
| Week 104 | -60.96 ± 32.259 | -49.35 ± 39.319 | -49.07 ± 29.091 | -38.70 ± 38.663 | -46.44 ± 31.668 | -52.14 ± 33.559 | -50.03 ± 26.905 |
| Week 156 | -71.10 ± 31.448 | -59.33 ± 40.055 | -47.31 ± 34.610 | -49.96 ± 27.555 | -44.69 ± 30.718 | -14.97 ± 58.982 | -62.80 ± 20.904 |
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
| scores on a scale | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Baseline | 1.78 ± 2.166 | 2.74 ± 2.422 | 1.84 ± 2.238 | 1.83 ± 2.102 | 1.21 ± 2.233 |
| Change from Baseline at Week 24 | -1.12 ± 2.566 | -3.15 ± 3.246 | -3.27 ± 3.532 | -3.12 ± 2.971 | -3.58 ± 3.042 |
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
| scores on a scale | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Baseline | 2.73 ± 2.328 | 2.43 ± 2.277 | 1.21 ± 2.607 | 2.21 ± 1.968 | 1.84 ± 2.238 | 1.83 ± 2.102 | 1.21 ± 2.233 |
| Change from Baseline at Week 52 | -4.70 ± 3.683 | -4.14 ± 3.592 | -3.83 ± 3.538 | -3.85 ± 3.211 | -3.48 ± 3.622 | -3.86 ± 3.395 | -3.66 ± 2.742 |
| Change from Baseline at Week 104 | -5.00 ± 4.153 | -4.25 ± 3.196 | -4.22 ± 3.667 | -5.11 ± 3.371 | -3.16 ± 3.516 | -3.56 ± 3.034 | -3.26 ± 3.034 |
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
| scores on a scale | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Baseline | 22.81 ± 20.843 | 16.26 ± 11.006 | 22.35 ± 20.878 | 24.63 ± 22.236 | 20.79 ± 16.192 |
| Change from Baseline at Week 24 | 0.38 ± 1.329 | -1.08 ± 3.867 | -2.43 ± 4.797 | -3.27 ± 6.744 | -2.71 ± 4.591 |
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
| scores on a scale | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Baseline | 9.18 ± 6.509 | 16.43 ± 11.979 | 24.50 ± 21.841 | 24.50 ± 18.798 | 22.35 ± 20.878 | 24.63 ± 22.236 | 20.79 ± 16.192 |
| Change from Baseline at Week 52 | -3.10 ± 3.814 | -1.86 ± 2.905 | -1.17 ± 3.486 | -1.92 ± 6.211 | -3.93 ± 7.191 | -5.71 ± 8.463 | -4.48 ± 6.127 |
| Change from Baseline at Week 104 | -3.89 ± 4.226 | -4.75 ± 5.994 | -5.11 ± 4.226 | -4.44 ± 7.367 | -8.00 ± 10.392 | -7.78 ± 8.695 | -6.26 ± 6.682 |
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
| percent change | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Percentage Area | 2.61 ± 9.497 | -10.61 ± 29.408 | -13.87 ± 25.296 | -14.09 ± 20.321 | -13.10 ± 17.605 |
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
| percent change | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52 | -32.01 ± 35.629 | -7.39 ± 21.571 | -10.57 ± 22.300 | -7.13 ± 25.967 | -19.73 ± 30.730 | -22.36 ± 23.593 | -25.41 ± 24.049 |
| Week 104 | -39.30 ± 37.071 | -23.05 ± 29.233 | -34.03 ± 27.992 | -18.49 ± 36.527 | -35.55 ± 34.039 | -30.40 ± 22.940 | -29.19 ± 39.767 |
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
| scores on a scale | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Baseline | 10.03 ± 3.515 | 9.29 ± 3.013 | 10.03 ± 3.945 | 9.97 ± 3.000 | 8.42 ± 3.464 |
| Change from Baseline at Week 24 | -1.15 ± 3.184 | -1.62 ± 2.282 | -1.57 ± 2.687 | -1.96 ± 3.561 | -0.74 ± 2.633 |
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
| scores on a scale | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Baseline | 8.64 ± 2.908 | 8.43 ± 2.901 | 11.29 ± 2.128 | 10.07 ± 3.668 | 10.03 ± 3.945 | 9.97 ± 3.000 | 8.42 ± 3.464 |
| Change from Baseline at Week 52 | -3.10 ± 3.247 | -1.29 ± 2.301 | -2.17 ± 3.157 | -2.62 ± 2.844 | -2.41 ± 3.030 | -3.48 ± 2.960 | -1.38 ± 2.555 |
| Change from Baseline at Week 104 | -3.44 ± 3.358 | -2.75 ± 3.694 | -2.22 ± 3.866 | -2.89 ± 1.537 | -2.84 ± 2.754 | -4.00 ± 3.049 | -1.68 ± 2.730 |
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
| percent change | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Percentage Change From Baseline in VETF Scale Scores at Week 24: Total Staging | -7.58 ± 18.740 | -17.52 ± 22.267 | -13.55 ± 21.200 | -17.00 ± 31.798 | -4.46 ± 38.916 |
The VETF-proposed system combines analysis of extent (0%-100% BSA), stage of disease (staging), and disease progression (spreading); each component is evaluated and reported independently. Staging is based on cutaneous and hair pigmentation in vitiligo patches. Disease is staged 0 to 4 on the largest macule in each of 5 body regions, except hands and feet, which are assessed separately and globally as 1 unique area. Stage 0=normal pigmentation, Stage 1=incomplete pigmentation, Stage 2=complete depigmentation (a few white hairs do not change stage), Stage 3=partial hair whitening (\<30%), Stage 4=complete hair whitening; total score of 0 (less severe disease) to 20 (more severe disease). Disease progression is based on assessing the largest patch in each of 5 body areas: -1=regressive vitiligo (ongoing subclinical repigmentation), 0=similar limits, 1=progressive vitiligo (ongoing subclinical depigmentation); total score of -5 (improving disease) to +5 (more severe disease spread).
| percent change | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52 | -33.48 ± 25.022 | -12.70 ± 24.012 | -17.31 ± 22.623 | -23.88 ± 19.262 | -21.45 ± 24.571 | -30.00 ± 22.563 | -12.99 ± 29.585 |
| Week 104 | -37.20 ± 29.132 | -24.29 ± 30.439 | -16.55 ± 27.268 | -32.06 ± 12.311 | -27.76 ± 23.202 | -35.20 ± 23.904 | -14.09 ± 26.969 |
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.
| percentage of participants | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 1 | 0.0 | 3.2 | 9.7 | 13.3 | 9.1 |
| 2 | 6.3 | 16.1 | 16.1 | 20.0 | 27.3 |
| 3 | 40.6 | 64.5 | 61.3 | 36.7 | 54.5 |
| 4 | 34.4 | 0.0 | 9.7 | 16.7 | 3.0 |
| Missing at the visit | 18.8 | 16.1 | 3.2 | 13.3 | 6.1 |
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.
| percentage of participants | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52, 0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.9 | 4.8 | 0.0 |
| Week 52, 1 | 20.0 | 14.3 | 8.3 | 7.7 | 10.3 | 14.3 | 24.1 |
| Week 52, 2 | 60.0 | 7.1 | 33.3 | 46.2 | 17.2 | 28.6 | 37.9 |
| Week 52, 3 | 20.0 | 71.4 | 50.0 | 46.2 | 55.2 | 42.9 | 31.0 |
| Week 52, 4 | 0.0 | 7.1 | 8.3 | 0.0 | 10.3 | 9.5 | 6.9 |
| Week 104, 0 | 0.0 | 0.0 | 11.1 | 11.1 | 5.3 | 11.1 | 15.8 |
| Week 104, 1 | 55.6 | 50.0 | 33.3 | 22.2 | 31.6 | 33.3 | 31.6 |
| Week 104, 2 | 33.3 | 25.0 | 33.3 | 22.2 | 36.8 | 27.8 | 26.3 |
| Week 104, 3 | 11.1 | 25.0 | 11.1 | 44.4 | 26.3 | 27.8 | 21.1 |
| Week 104, 4 | 0.0 | 0.0 | 11.1 | 0.0 | 0.0 | 0.0 | 5.3 |
| Week 156, 0 | 0.0 | 0.0 | 60.0 | 0.0 | 25.0 | 0.0 | 33.3 |
| Week 156, 1 | 0.0 | 50.0 | 0.0 | 60.0 | 12.5 | 37.5 | 55.6 |
| Week 156, 2 | 100.0 | 0.0 | 20.0 | 20.0 | 50.0 | 25.0 | 0.0 |
| Week 156, 3 | 0.0 | 50.0 | 20.0 | 20.0 | 12.5 | 37.5 | 11.1 |
| Week 156, 4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.
| percentage of participants | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 1 | 0.0 | 0.0 | 3.3 | 0.0 | 3.2 |
| 2 | 11.5 | 23.1 | 20.0 | 23.1 | 35.5 |
| 3 | 57.7 | 76.9 | 70.0 | 61.5 | 58.1 |
| 4 | 30.8 | 0.0 | 6.7 | 15.4 | 3.2 |
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening.
| percentage of participants | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52, 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Week 52, 1 | 10.0 | 0.0 | 0.0 | 0.0 | 10.3 | 0.0 | 6.9 |
| Week 52, 2 | 50.0 | 35.7 | 8.3 | 7.7 | 13.8 | 28.6 | 55.2 |
| Week 52, 3 | 40.0 | 57.1 | 83.3 | 84.6 | 69.0 | 61.9 | 31.0 |
| Week 52, 4 | 0.0 | 7.1 | 8.3 | 7.7 | 6.9 | 9.5 | 6.9 |
| Week 104, 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Week 104, 1 | 0.0 | 25.0 | 11.1 | 11.1 | 5.3 | 0.0 | 0.0 |
| Week 104, 2 | 77.8 | 37.5 | 33.3 | 33.3 | 68.4 | 55.6 | 63.2 |
| Week 104, 3 | 22.2 | 37.5 | 44.4 | 55.6 | 26.3 | 27.8 | 36.8 |
| Week 104, 4 | 0.0 | 0.0 | 11.1 | 0.0 | 0.0 | 16.7 | 0.0 |
| Week 156, 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Week 156, 1 | 50.0 | 50.0 | 20.0 | 0.0 | 25.0 | 0.0 | 11.1 |
| Week 156, 2 | 50.0 | 0.0 | 0.0 | 60.0 | 50.0 | 62.5 | 66.7 |
| Week 156, 3 | 0.0 | 50.0 | 60.0 | 40.0 | 25.0 | 25.0 | 22.2 |
| Week 156, 4 | 0.0 | 0.0 | 20.0 | 0.0 | 0.0 | 12.5 | 0.0 |
The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.
| percentage of participants | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 1 | 9.4 | 16.1 | 12.9 | 16.7 | 33.3 |
| 2 | 31.3 | 38.7 | 41.9 | 40.0 | 27.3 |
| 3 | 28.1 | 25.8 | 35.5 | 20.0 | 24.2 |
| 4 | 15.6 | 3.2 | 6.5 | 10.0 | 9.1 |
| Missing at the visit | 15.6 | 16.1 | 3.2 | 13.3 | 6.1 |
The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.
| percentage of participants | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52, 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.4 |
| Week 52, 1 | 50.0 | 21.4 | 16.7 | 30.8 | 24.1 | 30.0 | 44.8 |
| Week 52, 2 | 40.0 | 28.6 | 83.3 | 46.2 | 37.9 | 30.0 | 24.1 |
| Week 52, 3 | 10.0 | 50.0 | 0.0 | 23.1 | 34.5 | 30.0 | 20.7 |
| Week 52, 4 | 0.0 | 0.0 | 0.0 | 0.0 | 3.4 | 10.0 | 6.9 |
| Week 104, 0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.3 | 5.6 | 5.3 |
| Week 104, 1 | 66.7 | 50.0 | 22.2 | 55.6 | 42.1 | 44.4 | 36.8 |
| Week 104, 2 | 22.2 | 37.5 | 55.6 | 33.3 | 36.8 | 16.7 | 47.4 |
| Week 104, 3 | 11.1 | 12.5 | 22.0 | 11.1 | 15.8 | 22.2 | 5.3 |
| Week 104, 4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 11.1 | 5.3 |
| Week 156, 0 | 0.0 | 0.0 | 20.0 | 0.0 | 12.5 | 0.0 | 11.1 |
| Week 156, 1 | 50.0 | 50.0 | 0.0 | 80.0 | 37.5 | 37.5 | 44.4 |
| Week 156, 2 | 50.0 | 50.0 | 80.0 | 20.0 | 50.0 | 50.0 | 22.2 |
| Week 156, 3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 11.1 |
| Week 156, 4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.5 | 11.1 |
The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.
| percentage of participants | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| 0 | 0.0 | 0.0 | 3.2 | 0.0 | 0.0 |
| 1 | 6.3 | 12.9 | 9.7 | 16.7 | 15.2 |
| 2 | 37.5 | 35.5 | 38.7 | 33.3 | 45.5 |
| 3 | 31.3 | 29.0 | 35.5 | 30.0 | 21.2 |
| 4 | 9.4 | 6.5 | 9.7 | 6.7 | 12.1 |
| Missing at the visit | 15.6 | 16.1 | 3.2 | 13.3 | 6.1 |
The severity of vitiligo was assessed by the participant using the PaGVA, which has a 5-point scale. The participant was asked the following: How severe is your vitiligo on your face (or total body) with respect to the area covered by white skin? Responses: 0=no white patches (no vitiligo); 1=mild; 2=moderate; 3=severe; 4=very severe.
| percentage of participants | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52, 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Week 52, 1 | 20.0 | 7.1 | 8.3 | 0.0 | 13.8 | 25.0 | 13.8 |
| Week 52, 2 | 60.0 | 50.0 | 41.7 | 69.2 | 48.3 | 40.0 | 62.1 |
| Week 52, 3 | 20.0 | 42.9 | 50.0 | 23.1 | 27.6 | 25.0 | 10.3 |
| Week 52, 4 | 0.0 | 0.0 | 0.0 | 7.7 | 10.3 | 10.0 | 13.8 |
| Week 104, 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Week 104, 1 | 33.3 | 25.0 | 0.0 | 0.0 | 36.8 | 22.2 | 15.8 |
| Week 104, 2 | 55.6 | 50.0 | 44.4 | 77.8 | 42.1 | 44.4 | 57.9 |
| Week 104, 3 | 11.1 | 25.0 | 55.6 | 22.2 | 15.8 | 16.7 | 21.1 |
| Week 104, 4 | 0.0 | 0.0 | 0.0 | 0.0 | 5.3 | 16.7 | 5.3 |
| Week 156, 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Week 156, 1 | 50.0 | 25.0 | 20.0 | 20.0 | 37.5 | 12.5 | 33.3 |
| Week 156, 2 | 50.0 | 75.0 | 40.0 | 40.0 | 50.0 | 37.5 | 55.6 |
| Week 156, 3 | 0.0 | 0.0 | 40.0 | 40.0 | 12.5 | 25.0 | 0.0 |
| Week 156, 4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 25.0 | 11.1 |
The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.
| percentage of participants | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| 1 | 7.4 | 3.8 | 6.7 | 11.5 | 6.5 |
| 2 | 0.0 | 19.2 | 13.3 | 19.2 | 22.6 |
| 3 | 22.2 | 34.6 | 50.0 | 53.8 | 35.5 |
| 4 | 37.0 | 26.9 | 23.3 | 11.5 | 25.8 |
| 5 | 22.2 | 11.5 | 6.7 | 0.0 | 9.7 |
| 6 | 11.1 | 3.8 | 0.0 | 3.8 | 0.0 |
| 7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.
| percentage of participants | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52, 1 | 0.0 | 7.1 | 8.3 | 7.7 | 10.3 | 4.8 | 13.8 |
| Week 52, 2 | 30.0 | 14.3 | 25.0 | 23.1 | 20.7 | 47.6 | 31.0 |
| Week 52, 3 | 30.0 | 42.9 | 58.3 | 46.2 | 55.2 | 38.1 | 27.6 |
| Week 52, 4 | 20.0 | 7.1 | 8.3 | 15.4 | 6.9 | 9.5 | 20.7 |
| Week 52, 5 | 20.0 | 28.6 | 0.0 | 7.7 | 3.4 | 0.0 | 6.9 |
| Week 52, 6 | 0.0 | 0.0 | 0.0 | 0.0 | 3.4 | 0.0 | 0.0 |
| Week 52, 7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Week 104, 1 | 11.1 | 25.0 | 11.1 | 22.2 | 10.5 | 22.2 | 21.1 |
| Week 104, 2 | 33.3 | 12.5 | 44.4 | 33.3 | 36.8 | 38.9 | 36.8 |
| Week 104, 3 | 22.2 | 62.5 | 33.3 | 22.2 | 47.4 | 22.2 | 36.8 |
| Week 104, 4 | 22.2 | 0.0 | 11.1 | 22.2 | 5.3 | 11.1 | 0.0 |
| Week 104, 5 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.3 |
| Week 104, 6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.6 | 0.0 |
| Week 104, 7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Week 156, 1 | 50.0 | 25.0 | 20.0 | 20.0 | 12.5 | 12.5 | 11.1 |
| Week 156, 2 | 50.0 | 25.0 | 20.0 | 60.0 | 25.0 | 50.0 | 77.8 |
| Week 156, 3 | 0.0 | 50.0 | 40.0 | 0.0 | 62.5 | 12.5 | 11.1 |
| Week 156, 4 | 0.0 | 0.0 | 20.0 | 20.0 | 0.0 | 0.0 | 0.0 |
| Week 156, 5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.5 | 0.0 |
| Week 156, 6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.5 | 0.0 |
| Week 156, 7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.
| percentage of participants | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Percentage of Participants Who Report a PaGIC-V Score of Very Much Improved or Much Improved at Week 24 | 7.4 | 23.1 | 20.0 | 30.8 | 29.0 |
The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.
| percentage of participants | Ruxolitinib Cream 0.15% QD | Vehicle/Ruxolitinib Cream 0.15% QD to 0.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% QD: 1.5% BID | Vehicle/Ruxolitinib Cream 0.15% QD to 1.5% BID: 1.5% BID | Ruxolitinib Cream 0.5% QD: 1.5% BID | Ruxolitinib Cream 1.5% QD: 1.5 % BID | Ruxolitinib Cream 1.5% BID: 1.5% BID |
|---|---|---|---|---|---|---|---|
| Week 52 | 30.0 | 21.4 | 33.3 | 30.8 | 31.0 | 52.4 | 44.8 |
| Week 104 | 44.4 | 37.5 | 55.6 | 55.6 | 47.4 | 61.1 | 57.9 |
| Week 156 | 100.0 | 50.0 | 40.0 | 80.0 | 37.5 | 62.5 | 88.9 |
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| days | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Time to Achieve an F-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the F-VASI50 Score | NA (NA to NA) | 197.0 (127.0 to NA) | 339.0 (195.0 to NA) | 172.0 (127.0 to 323.0) | 170.0 (127.0 to NA) |
A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI. T-VASI was measured by the percentage of vitiligo involvement from all body regions (percentage of BSA; assessed by the Investigator) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was derived by multiplying the vitiligo involvement values by the percentage of affected skin for each body site and summing all values (possible range: 0-100; lower scores indicate increased improvement).
| days | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Time to Achieve a T-VASI50: Number of Days From the Date of the First Application in the Double-Blind Period to the Date of the First Evaluation at Which the Participant Met the T-VASI50 Score | NA (NA to NA) | NA (204.0 to NA) | NA (366.0 to NA) | NA (192.0 to NA) | 376.0 (276.0 to NA) |
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening. Time to achieve an F-PhGVA response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the F-PhGVA score.
| days | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Time to Achieve an F-PhGVA of Clear or Almost Clear | NA (NA to NA) | 372.0 (274.0 to NA) | NA (369.0 to NA) | NA (NA to NA) | NA (367.0 to NA) |
The severity of vitiligo was assessed by the physician using the PhGVA, which has a 5-point scale. 0=clear, no signs of vitiligo; 1=almost clear, only specks of depigmentation present; 2=mild disease, pigmented and depigmented areas are equal; 3=moderate disease, more or complete depigmentation (may include \< 30% hair whitening); 4=severe disease, complete depigmentation plus \> 30% hair whitening. Time to achieve a T-PhGVA response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the T-PhGVA score.
| days | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Time to Achieve an T-PhGVA of Clear or Almost Clear | NA (NA to NA) | 372.0 (274.0 to NA) | NA (NA to NA) | NA (NA to NA) | NA (369.0 to NA) |
The PaGIC-V is an assessment of improvement by the participant. It is a 7-point scale comparing the vitiligo areas at Baseline with the participant's treated areas of vitiligo at the study visit. The participant answered the following: "Since the start of the treatment you've received in this study, your vitiligo in areas treated with the study drug is: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse. Time to achieve a PaGIC-V response was defined as the number of days from the date of the first application in the Double-Blind Period to the date of the first evaluation at which the participant met the PaGIC-V score.
| days | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Time to Achieve a PaGIC-V of Very Much Improved or Much Improved | NA (NA to NA) | NA (274.0 to NA) | NA (290.0 to NA) | 282.0 (169.0 to NA) | 281.0 (178.0 to NA) |
Collected over Up to 180 weeks (156-week treatment period plus 6-month follow-up period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle Twice Daily (BID) | 0/32 (0%) | 0/32 (0%) | 14/32 (43.8%) |
| Ruxolitinib Cream 0.15% Once Daily (QD) | 0/31 (0%) | 0/31 (0%) | 19/31 (61.3%) |
| Ruxolitinib Cream 0.5% QD | 0/45 (0%) | 2/45 (4.4%) | 23/45 (51.1%) |
| Ruxolitinib Cream 1.5% QD | 0/44 (0%) | 1/44 (2.3%) | 20/44 (45.5%) |
| Ruxolitinib Cream 1.5% BID | 0/130 (0%) | 4/130 (3.1%) | 45/130 (34.6%) |
| Event | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% Once Daily (QD) | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| SeizureNervous system disorders | 0/32 | 0/31 | 0/45 | 1/44 | 0/130 |
| Coronary artery occlusionCardiac disorders | 0/32 | 0/31 | 1/45 | 0/44 | 0/130 |
| Oesophageal achalasiaGastrointestinal disorders | 0/32 | 0/31 | 1/45 | 0/44 | 0/130 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/32 | 0/31 | 0/45 | 0/44 | 1/130 |
| Cholecystitis acuteHepatobiliary disorders | 0/32 | 0/31 | 0/45 | 0/44 | 1/130 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/32 | 0/31 | 0/45 | 0/44 | 1/130 |
| Subdural haematomaInjury, poisoning and procedural complications | 0/32 | 0/31 | 0/45 | 0/44 | 1/130 |
| Event | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% Once Daily (QD) | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|---|
| Application site pruritusGeneral disorders | 3/32 | 6/31 | 3/45 | 3/44 | 2/130 |
| BronchitisInfections and infestations | 0/32 | 5/31 | 0/45 | 1/44 | 6/130 |
| AcneSkin and subcutaneous tissue disorders | 1/32 | 4/31 | 5/45 | 4/44 | 12/130 |
| NasopharyngitisInfections and infestations | 4/32 | 4/31 | 5/45 | 5/44 | 6/130 |
| PruritusSkin and subcutaneous tissue disorders | 3/32 | 1/31 | 5/45 | 5/44 | 6/130 |
| Upper respiratory tract infectionInfections and infestations | 0/32 | 1/31 | 5/45 | 1/44 | 8/130 |
| Skin exfoliationSkin and subcutaneous tissue disorders | 1/32 | 3/31 | 1/45 | 1/44 | 1/130 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 3/32 | 0/31 | 1/45 | 2/44 | 1/130 |
| HeadacheNervous system disorders | 3/32 | 1/31 | 0/45 | 3/44 | 2/130 |
| SinusitisInfections and infestations | 1/32 | 2/31 | 1/45 | 2/44 | 9/130 |
| Age, Continuous(Years) | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID | Total |
|---|---|---|---|---|---|---|
| Mean | 46.3 ± 13.11 | 45.1 ± 11.46 | 53.8 ± 14.34 | 46.7 ± 11.73 | 49.5 ± 12.28 | 48.3 ± 12.85 |
| Sex: Female, Male(Participants) | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID | Total |
|---|---|---|---|---|---|---|
| Female | 20 | 18 | 12 | 19 | 15 | 84 |
| Male | 12 | 13 | 19 | 11 | 18 | 73 |
| Race/Ethnicity, Customized(Participants) | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 6 | 6 | 6 | 5 | 33 |
| Not Hispanic or Latino | 21 | 22 | 23 | 21 | 27 | 114 |
| Not Reported | 1 | 2 | 1 | 3 | 0 | 7 |
| Unknown | 0 | 0 | 0 | 0 | 1 | 1 |
| Captured as "Other" | 0 | 1 | 1 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID | Total |
|---|---|---|---|---|---|---|
| White/Caucasian | 26 | 29 | 25 | 23 | 29 | 132 |
| Black/African-American | 5 | 0 | 4 | 2 | 3 | 14 |
| Asian | 1 | 0 | 1 | 2 | 1 | 5 |
| Mexican | 0 | 1 | 0 | 0 | 0 | 1 |
| Nigerian/West African | 0 | 1 | 0 | 0 | 0 | 1 |
| Cuban | 0 | 0 | 1 | 0 | 0 | 1 |
| Spanish | 0 | 0 | 0 | 1 | 0 | 1 |
| Hispanic | 0 | 0 | 0 | 1 | 0 | 1 |
| Caucasian, Black, and Asian | 0 | 0 | 0 | 1 | 0 | 1 |
| Facial Body Surface Area (F-BSA) Involvement(percentage of facial surface area) | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID | Total |
|---|---|---|---|---|---|---|
| Mean | 1.44 ± 0.838 | 1.35 ± 0.858 | 1.40 ± 0.760 | 1.67 ± 0.953 | 1.55 ± 0.892 | 1.48 ± 0.858 |
| Total Body Surface Area (T-BSA) Involvement(percentage of total body surface area) | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID | Total |
|---|---|---|---|---|---|---|
| Mean | 23.54 ± 20.960 | 17.56 ± 10.925 | 22.96 ± 21.449 | 24.81 ± 20.056 | 21.46 ± 16.820 | 22.05 ± 18.377 |
| Face Vitiligo Area Scoring Index (F-VASI)(scores on a scale) | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID | Total |
|---|---|---|---|---|---|---|
| Mean | 1.21 ± 0.845 | 1.19 ± 0.754 | 1.22 ± 0.705 | 1.45 ± 0.980 | 1.26 ± 0.807 | 1.26 ± 0.817 |
| Total Body Vitiligo Area Scoring Index (T-VASI)(scores on a scale) | Vehicle Twice Daily (BID) | Ruxolitinib Cream 0.15% QD | Ruxolitinib Cream 0.5% QD | Ruxolitinib Cream 1.5% QD | Ruxolitinib Cream 1.5% BID | Total |
|---|---|---|---|---|---|---|
| Mean | 19.40 ± 18.512 | 14.57 ± 9.049 | 18.43 ± 15.363 | 20.55 ± 18.488 | 16.94 ± 14.256 | 17.96 ± 15.451 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2017 to primary completion in Sep 2018, 15 months.
Results were first posted in Dec 2021, 3 years 2 months after primary completion. A results delay was requested in Sep 2019.
Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib